Conv. Plasma
Nigella Sativa
Peg.. Lambda

All HCQ studies
Meta analysis
Home COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  

Finding the Dose for Hydroxychloroquine Prophylaxis for COVID-19: The Desperate Search for Effectiveness

Al-Kofahi et al., Clin. Pharmacol. Ther., Jun 1, 2020, doi:10.1002/cpt.1874
Jun 2020  
  Source   PDF   All Studies   Meta AnalysisMeta
Analysis of HCQ dosing regimens, recommending:
PrEP: 800mg loading dose followed by 400mg 2 or 3 times weekly to maintain weekly troughs above EC50 in >50% of patients at steady-state.
PEP: 800mg loading dose followed in 6 hours by 600mg, then 600mg daily for 4 more days to achieve daily troughs above EC50 in >50% subjects.
Al-Kofahi et al., 1 Jun 2020, peer-reviewed, 9 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Finding the Dose for Hydroxychloroquine Prophylaxis for COVID‐19: The Desperate Search for Effectiveness
Mahmoud Al‐kofahi, Pamala Jacobson, David R Boulware, Arthur Matas, Raja Kandaswamy, Mutaz M Jaber, Radha Rajasingham, Jo‐anne H Young, Melanie R Nicol
Clinical Pharmacology & Therapeutics, doi:10.1002/cpt.1874
Study Highlights WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?  Hydroxychloroquine is currently of interest for treatment and prevention of coronavirus disease 2019 (COVID-19). In the absence of therapeutic efficacy targets, optimal dosing is unknown. WHAT QUESTION DID THIS STUDY ADDRESS?  We examined various hydroxychloroquine dosing strategies and compared predicted plasma exposures to in vitro efficacy targets. WHAT DOES THIS STUDY ADD TO OUR KNOW-LEDGE?  Conventional malaria prevention and treatment dosing may not be sufficient to reach plasma concentrations that would be expected to inhibit or suppress severe acute respiratory syndrome coronavirus 2. HOW MIGHT THIS CHANGE CLINICAL PHARMA-COLOGY OR TRANSLATIONAL SCIENCE?  These findings are intended to guide the research community in optimizing dose selection for COVID-19 prevention and early treatment trials.
SUPPORTING INFORMATION Supplementary information accompanies this paper on the Clinical Pharmacology & Therapeutics website ( FUNDING Support for this study was received from the National Institute of Allergy and Infectious Diseases (K08 AI134262 for M.R.N.); (R01AI140303 for P.A.J.); and (U01AI125003 for D.R.B.). CONFLICT OF INTEREST The authors declared no competing interests for this work. AUTHOR CONTRIBUTIONS
Al-Rawi, Meggitt, Williams, Wahie, Steadystate pharmacokinetics of hydroxychloroquine in patients with cutaneous lupus erythematosus, Lupus
Chen, A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19, COVID
Chhonker, Sleightholm, Li, Oupický, Murry, Simultaneous quantitation of hydroxychloroquine and its metabolites in mouse blood and tissues using LC-ESI-MS/MS: an application for pharmacokinetic studies, J. Chromatogr. B Analyt. Technol. Biomed. Life Sci
Dong, Hu, Gao, Discovering drugs to treat coronavirus disease 2019 (COVID-19), Drug. Discov. Ther
Garcia-Cremades, Optimizing hydroxychloroquine dosing for patients with COVID-19: An integrative modeling approach for effective drug repurposing, Clin. Pharmacol. Ther, doi:10.1002/cpt.1856
Gautret, Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int. J. Antimicrob. Agents, doi:10.1016/j.ijantimicag.2020.105949
Lim, Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by plasmodium vivax, Antimicrob. Agents Chemother
Liu, Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro, Cell. Discov
Mclachlan, Cutler, Tett, Plasma protein binding of the enantiomers of hydroxychloroquine and metabolites, Eur. J. Clin. Pharmacol
Perinel, Towards optimization of hydroxychloroquine dosing in intensive care unit COVID-19 patients, Clin. Infect. Dis, doi:10.1093/cid/ciaa394
Warhurst, Steele, Adagu, Craig, Cullander, Hydroxychloroquine is much less active than chloroquine against chloroquine-resistant Plasmodium falciparum, in agreement with its physicochemical properties, J. Antimicrob. Chemother
Yao, In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Clin. Infect. Dis, doi:10.1093/cid/ciaa237
Zeitlinger, Protein binding: do we ever learn?, Antimicrob. Agents. Chemother
Zhejiang, None, Med. Sci, doi:10.3785/j.issn.1008-9292.2020.03.03
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop